The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the ...

Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Eli Lilly has broken free from the Big Pharma pack. Fueled by sky-high expectations for the GLP-1 market, Lilly has achieved ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the ...

Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...

If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...